Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
You may also be interested in...
Long-acting injectable aripiprazole lauroxil cleared six weeks late, but Alkermes is happy with label's flexibility on dosing, saying product will be differentiated from Abilify Maintena.
The pharma firm, looking to counter generic competition, is partnering with Proteus Digital Health on a first-of-a-kind FDA submission for a combination product of antipsychotic drug Abilify embedded with an ingestible sensor to measure adherence and physiologic response.
First-of-its-kind NDA is for a combination product of Abilify embedded with an ingestible sensor to measure adherence and physiologic response. Otsuka sees opportunities to extend brand facing generic competition and for combo approach with future medicines too.